THIS MAY BE BIG: new monoclonalantibody-peptide conjugate crosses blood-brainbarrier

[Lani]

in mice

Let's get the clinical trial started soon!

Mol Cancer Ther. 2014 Dec 9. [Epub ahead of print]

ANG4043, a Novel Brain-Penetrant Peptide-mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice.

Regina A1, Demeule M1, Tripathy S1, Lord-Dufour S1, Currie JC1, Iddir M2, Annabi B2, Castaigne JP1, Lachowicz JE3.
Author information


Abstract

Anti-HER2 monoclonal antibodies (mAb) have been shown to reduce tumor size and increase survival in patients with breast cancer, but they are ineffective against brain metastases due to poor brain penetration. In previous studies, we identified a peptide, known as Angiopep-2 (An2), which crosses the blood-brain barrier (BBB) efficiently via receptor-mediated transcytosis, and, when conjugated, endows small molecules and peptides with this property. Extending this strategy to higher molecular weight biologics, we now demonstrate that a conjugate between An2 and an anti-HER2 mAb results in a new chemical entity, ANG4043, which retains in vitro binding affinity for the HER2 receptor and antiproliferative potency against HER2-positive BT-474 breast ductal carcinoma cells. Unlike the native mAb, ANG4043 binds LRP1 clusters and is taken up by LRP1-expressing cells. Measuring brain exposure after intracarotid delivery, we demonstrate that the new An2-mAb conjugate penetrates the BBB with a rate of brain entry (Kin) of 1.6 × 10-3 mL/g/s. Finally, in mice with intracranially implanted BT-474 xenografts, systemically administered ANG4043 increases survival. Overall, this study demonstrates that the incorporation of An2 to the anti-HER2 mAb confers properties of increased uptake in brain endothelial cells as well as BBB permeability. These characteristics of ANG4043 result in higher exposure levels in BT-474 brain tumors and prolonged survival following systemic treatment. Moreover, the data further validate the An2-drug conjugation strategy as a way to create brain-penetrant biologics for neuro-oncology and other CNS indications. Mol Cancer Ther; 1-12. ©2014 AACR.
©2014 American Association for Cancer Research.


PMID: 25492620 [PubMed - as supplied by publisher]

[ariana]

Oh MY that is good news !!!!

[forher]

Thank you for this! Hoping the trials begin soon.

[Lien]

If this pans out, it is a major breakthrough and yet another nail in Her2positive BC's coffin. Let's see how it works out in trials. May they start soon!

Jacqueline

[Lani]

bringing this up so ROLEPAUL can see it if he missed it

[karina14]

We need something like this badly...

Lani, you are such a treasure for bringing them up! No mater where we look for info we can't find it all, and you bring it all here! We love you :-)

[Rolepaul]

Funny. I saw this and saw the results on the MRI scans with Nina's brain lesions. Are the researcher's missing something with conjugated antibodies and water/lipid solubility thinking. If the MAb is water soluble and the BBB prevents the MAb penetrating to help by forming a fat film, conjugating the non-water soluble cancer drug may work because it allows the MAb to to get through the BBB, not because it makes the conjugate more deadly to the cancer cell. Maybe the concept is to conjugate a fat like substance, which is cheap versus the cancer drugs. Another thing to ask a MAb guru.